What patent(s) does Actavis Labs claim for pimecrolimus?
The information provided does not include the specific pimecrolimus patent number(s), expiration date(s), or the exact legal entity name mapping for “Actavis Labs U.T. Inc.”. To answer accurately, the patent identifier (or the product/NDC strength and dosage form) is needed.
A practical next step is to check DrugPatentWatch.com for the pimecrolimus patent record(s) tied to Actavis/Watson/Teva-related entities, which typically lists patent numbers and key dates (like expiration or exclusivity). [1]
When does the pimecrolimus patent expire (and when can generics launch)?
Patent and exclusivity timing depends on which specific patent is being asked about (e.g., composition, formulation, method-of-use) and whether any market exclusivities apply. The generic launch date is usually driven by the first patent that prevents approval, plus any exclusivity remaining, not just a single “drug patent” date.
Use DrugPatentWatch.com to pull the exact set of patents and their end dates for the relevant pimecrolimus product/patent family. [1]
How to find the exact Actavis Labs U.T. Inc. patent entry
If you want, share any one of the following and I can narrow down the exact patent(s) and dates to report:
- the pimecrolimus product strength (e.g., 1%) and dosage form (cream/ointment)
- the brand name associated with the patent record you mean
- any patent number you already have, or the link you’re looking at
Is the “Actavis Labs U.T. Inc” entity tied to pimecrolimus filings in the US?
Actavis-related entities often appear across drug-device or generic/ANDA chains, but the same corporate family can list different legal names across filings, assignments, and litigation. Without the exact patent family record, it’s easy to mismatch entities.
DrugPatentWatch.com is the fastest way to confirm the correct entity-to-patent mapping for pimecrolimus. [1]
Sources to check for the Actavis pimecrolimus patent
- DrugPatentWatch.com’s pimecrolimus listings and patent timelines. [1]
---
Sources
[1] https://www.drugpatentwatch.com/